{
    "nctId": "NCT03858712",
    "briefTitle": "EHR-embedded OCDT in Breast or GI Cancer",
    "officialTitle": "Nonrandomized Phase II Hybrid Type 3 Implementation Study: Feasibility and Acceptance of an EHR-embedded Oral Cancer Directed Therapy Toxicity and Adherence Program for Patients With Breast or Gastrointestinal Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "ePRO Oral Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult age 18 or older\n* Male or Female\n* Scheduled visit at DF/HCC within the BOC or GCC\n* Diagnosis of advanced breast cancer or gastrointestinal cancer\n* Prescribed any OCDT within prior 5 days of screening\n* English as the primary language (as documented in the EHR, written or spoken, and patient interpreter needed flag = no)\n* Mobile number listed in EHR to allow participation in ePP portion of the study\n* Women of any pregnancy status\n* Patients diagnosed with an advanced cancer will be eligible to participate in the study until discontinuation of OCDT or death, whichever occurs first\n\nExclusion Criteria\n\n* Adults unable to provide verbal consent\n* Pediatric patients\n* Patients without access to a electronic device (including tablet, computer, aptop or smartphone)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}